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Epigenetic changes in 
myelofibrosis: Distinct methylation 
changes in the myeloid 
compartments and in cases with 
ASXL1 mutations
Helene Myrtue Nielsen1,2,3, Christen Lykkegaard Andersen1,4, Maj Westman5, Lasse Sommer 
Kristensen1, Fazila Asmar1, Torben Arvid Kruse6, Mads Thomassen6, Thomas Stauffer Larsen7, 
Vibe Skov4, Lise Lotte Hansen  2, Ole Weis Bjerrum1, Hans Carl Hasselbalch4, Vasu Punj8 & 
Kirsten Grønbæk1,3
This is the first study to compare genome-wide DNA methylation profiles of sorted blood cells from 
myelofibrosis (MF) patients and healthy controls. We found that differentially methylated CpG sites 
located to genes involved in ‘cancer’ and ‘embryonic development’ in MF CD34+ cells, in ‘inflammatory 
disease’ in MF mononuclear cells, and in ‘immunological diseases’ in MF granulocytes. Only few 
differentially methylated CpG sites were common among the three cell populations. Mutations in 
the epigenetic regulators ASXL1 (47%) and TET2 (20%) were not associated with a specific DNA 
methylation pattern using an unsupervised approach. However, in a supervised analysis of ASXL1 
mutated versus wild-type cases, differentially methylated CpG sites were enriched in regions marked 
by histone H3K4me1, histone H3K27me3, and the bivalent histone mark H3K27me3 + H3K4me3 in 
human CD34+ cells. Hypermethylation of selected CpG sites was confirmed in a separate validation 
cohort of 30 MF patients by pyrosequencing. Altogether, we show that individual MF cell populations 
have distinct differentially methylated genes relative to their normal counterparts, which likely 
contribute to the phenotypic characteristics of MF. Furthermore, differentially methylated CpG sites in 
ASXL1 mutated MF cases are found in regulatory regions that could be associated with aberrant gene 
expression of ASXL1 target genes.
The chronic myeloproliferative neoplasms (MPNs) include the classical diseases myelofibrosis (MF), poly-
cythemia vera (PV), and essential thrombocythemia (ET), with MF patients having the highest morbidity and 
mortality1. In addition to the expansion of one or more of the myeloid lineages, MF is characterized by progres-
sive bone marrow fibrosis leading to extramedullary hematopoiesis and hepatosplenomegaly2.
The most commonly observed mutation in MF is JAK2V617F, which is found in 60% of MF patients3. Eight 
to 11% of JAK2V617F negative MF patients carry MPL mutations4, and both JAK2 and MPL mutations cause 
constitutive activation of the JAK/STAT pathway that promotes cell survival and proliferation5. More recently, 
mutations were identified in CALR that are mutually exclusive to JAK2 and MPL mutations in the majority of 
patients6, 7. In addition to causing constitutive activation of the JAK/STAT pathway7, mutated CALR lose the 
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ability to bind calcium and retrieve and retain chaperone proteins to the endoplasmic reticulum6, 7. Although 
mutations in JAK2, MPL, and CALR are recurrent in MPN, they alone explain neither the pathogenesis nor the 
clinical manifestations associated with the distinctive MPN subgroups.
Mutations in epigenetic regulators, including ASXL1, TET2, DNMT3A, EED, EZH2, IDH1/2, JARID2, and 
SUZ12 have also been observed in MF8, 9, and expansion of the ASXL1 mutated clone has been associated with 
leukemic transformation10. However, despite high frequency of mutations in some of these genes, little is known 
about their impact on epigenetic regulation in MF. Few studies have investigated the genome-wide methylation 
patters in MF11, 12, and none of them have compared different MF cell populations.
Both TET2 and ASXL1 mutations have been associated with increased DNA methylation levels when analyz-
ing neutrophils11, and unsorted cells from bone marrow and peripheral blood12. In addition, ASXL1 mutations 
were associated with a distinct DNA methylation signature11. Disruption of ASXL1 is frequent in myeloid malig-
nancies with a prevalence of 20–30%13–15. In vivo analysis shows that hematopoiesis-specific loss of Asxl1 causes 
multi lineage cytopenia and dysplasia13 indicating its pivotal role in hematopoiesis. ASXL1 and BAP1 constitute 
a deubiquitination complex, where BAP1 catalyze the deubiquitination of H2AK119Ub16, 17. H2AK119Ub is a 
repressive histone mark deposited by the Polycomb Repressive Complex 1 (PRC1)18, both in a PRC2-dependent19 
and independent manner20. Moreover, it was recently observed that H2AK119Ub could recruit components of 
the PRC2 complex to catalyze H3K27me321.
Since MF is a disease affecting several hematopoietic cell lineages, we investigated the genome-wide DNA 
methylation profiles of CD34+ cells, mononuclear cells, and granulocytes from 16 MF patients and 3 healthy 
age-matched controls. We further aimed to investigate whether distinct DNA methylation profiles are related to 
genetic aberrations of any of the epigenetic modifiers ASXL1, TET2, DNMT3A, IDH1, and IDH2.
Results
By comparison of individual MF cell populations to their normal counterparts isolated from healthy donors, we 
initially identified differentially methylated CpG sites within MF granulocytes, MF mononuclear cells and MF 
CD34+ cells, respectively.
MF granulocytes are hypomethylated relative to MF CD34+ cells and MF mononuclear 
cells. Based on the 504 most differentially methylated CpG sites with a standard deviation (SD) > 0.3 across 
all samples, a hierarchical cluster analysis clearly distinguished individual samples of MF mononuclear cells and 
MF CD34+ cells from MF granulocytes (Figure S1). In general, granulocytes were characterized by an overall 
low methylation level, which correlates to previous findings22. A single MF granulocyte sample (F16) clustered 
together with the mononuclear cells and CD34+ cells due to a higher overall methylation level. Three distinct 
clusters were observed in the granulocyte population; however, this could not be explained by mutations in any 
of the genes investigated.
Each MF cell compartment has a specific DNA methylation profile. A Venn diagram was used to 
illustrate the overlap of differentially methylated CpG sites between the MF granulocytes, MF mononuclear cells 
and MF CD34+ cells. The 200 most significantly differentially methylated CpG sites were included, and only a 
minor overlap was observed between the three MF cell populations (Fig. 1).
Aberrantly methylated genes in the MF CD34 + cell population. In the MF CD34+ cells, 1628 CpG 
sites annotated to 739 genes were differentially methylated (FDR p < 0.05; |Δβ| ± 0.2) when compared to their 
healthy counterparts (Table S2). Ingenuity pathway analysis revealed that differentially methylated CpG sites were 
annotated to genes involved in ‘cancer’ (e.g. WT1, BCL2, BIN1, GATA6, RUNX2, EGFR) and ‘embryonic develop-
ment’ (e.g. WT1, BMP4, FOXC1, GATA4), ‘cell death and survival’ (e.g. BCL2, EGFR, BMP4) ‘hematopoiesis’ (e.g. 
BMP4), ‘cell cycle’ (e.g. EGFR, BMP4), and ‘hematological diseases’(e.g. JAK2) (Figure S2A).
Aberrantly methylated genes in the MF mononuclear cells. In MF mononuclear cells, 213 CpG 
sites annotated to 121 genes were differentially methylated (FDR p < 0.05; |Δβ| ± 0.2) when compared to their 
healthy counterparts (Table S3). Ingenuity pathway analysis revealed that differentially methylated CpG sites were 
annotated to genes involved in ‘cell cycling’ (e.g. NDRG1, NEDD1, and MAD1L1), ‘inflammatory diseases’ (e.g. 
PRTN3), and ‘cancer’ (PCDHA6, MUC4, and ATP2C2) (Figure S2B).
Aberrantly methylated genes in the MF granulocyte population. In the MF granulocytes, 519 CpG 
sites annotated to 303 genes were differentially methylated (FDR p < 0.05; |Δβ| ± 0.3) when compared to their 
healthy counterparts (Table S4). Ingenuity pathway analysis revealed that differentially methylated CpG sites 
were annotated to genes involved in ‘cancer’ (e.g. WT1, BIN1, PCDHA6, RIPK4, SOCS3, KTN1), ‘cellular growth 
and proliferation’ (e.g. mir-146, WT1, FOXP1, CEBPE, IGF2BP1, IGF1R, CASP8), ‘immunological diseases’ (e.g. 
BCL2L1 and MICA) and in ‘cell death and survival’ (e.g. SOCS3, mir-146, UHRF1, and CASP8) (Figure S2C).
Investigation of differentially methylated CpG sites in the validation cohort. We selected four 
genes (LEP, TRIM59, WT1, and ZNF577) with at least two differentially methylated CpG sites in close proximity 
to the transcription start site for further validation. Differential methylation was confirmed using pyrosequencing 
for all genes in the MF validation cohort comprising 30 MF whole blood samples compared to 11 whole blood 
samples from healthy individuals (Fig. 2).
Somatic mutations in the MF cases. The mutational status of JAK2 was determined for all 16 MF 
patients (Table 1), whereas the mutational status of TET2, ASXL1, DNMT3A, IDH1, IDH2, CALR, and MPL was 
only determined in 15 patients due to limited material (Table 2). The most frequent mutations in the epigenetic 
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Figure 1. Venn diagram showing the overlap of differentially methylated CpG sites between MF cell 
populations. The CD34+ cell population is blue, the MF granulocyte population is yellow, and the MF 
mononuclear cell population is red. Five differentially methylated CpG sites overlapped between the three cell 
populations.
Figure 2. Validation of the methylated genes in a validation MF cohort. The DNA methylation level of 2–8 
CpG sites annotated to four genes (ZNF577, WT1, LEP, and TRIM59) was validated in a validation MF 
cohort consisting of 30 MF patients where DNA had been isolated from whole blood. Hypermethylation of 
the ZNF577, LEP, and TRIM59 promoter regions and the WT1 gene body was verified using pyrosequencing 
(P ≤ 0.001 for all genes analyzed, Mann-Whitney test).
www.nature.com/scientificreports/
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regulators were nonsense mutations predicted to cause premature termination in ASXL1, which was observed in 
six patients (no. 1, 3, 5, 10, 14, and 15). Patient 7 had a missense mutation in ASXL1 causing the p.N986S substi-
tution. Truncating mutations in the TET2 gene were observed for three patients (no. 1, 5, and 12), whereas two 
patients (no. 8 and 16) carried a previously unreported missense variant (c.1162 T > A) causing p.S388T. A skin 
biopsy from patient 8 was positive for the c.1162 T > A variant indicating its germ-line origin (data not shown). 
No mutations were identified in DNMT3A, IDH1 or IDH2.
Activating mutations of JAK2 were detected in 11/16 patients (no. 1, 4, 5, 7, 8, 9, 11, 12, 13, 14, and 15) whereas 
the frameshift CALR mutation p.L367fs*46, predicted to cause a C-terminal truncation, was observed in three 
patients (no. 3, 6, and 16). The activating MPL mutation p.W515L was detected in the two patients without JAK2 
and CALR mutations (no. 2 and 10).
Unsupervised cluster analysis did not reveal a genome-wide specific DNA methylation profile 
associated with ASXL1 or TET2 mutations in MF granulocytes or CD34+ cells. An unsupervised 
clustering of granulocytes and CD34+ cells did not identify differential methylation signatures associated with 
ASXL1 and TET2 mutated cases (Figs 3 and S3). RPMM clustering of the 519 CpG sites differentially methylated 
among MF granulocyte samples and their healthy age-matched controls show three distinct clusters (Fig. 3). 
Cluster one (light blue) included samples from three patients, whereas cluster two (pink) included the three 
healthy age-matched controls and a single MF sample (F9). Cluster three (grey) included the remaining 12 MF 
samples. ASXL1 mutations were observed in one of two analyzed cases in cluster one and in 50% of patients in 
cluster 3, indicating that ASXL1 mutations do not seem to correlate with a specific DNA methylation profile using 
an unsupervised approach, which is in contrast to a previous study of 12 patients11.
ASXL1 mutations are associated with differential DNA methylation of tumor suppressors and 
oncogenes in MF CD34+ cells. We next performed a supervised cluster analysis to investigate the asso-
ciation between mutated ASXL1 cases and aberrant DNA methylation in MF CD34+ cells. We identified 308 
differentially methylated CpG sites (with FDR p < 0.05; |Δβ| ± 0.2) annotated to 174 genes (Table S5) associ-
ated with mutated ASXL1, which we named the “ASXL1 methylation signature” (Fig. 4). Of the 308 CpG sites 
124 were hypermethylated while 184 were hypomethylated. In the granulocyte population a supervised clus-
ter analysis identified 281 differentially methylated CpG sites (with FDR p < 0.05; |Δβ| ± 0.3) annotated to 137 
genes (Table S6) associated with mutated ASXL1. Of the 281 CpG sites 105 were hypermethylated while 176 were 
hypomethylated. Several tumor suppressors and oncogenes including RASSF1, miR-663, ARID5B, FIP1L1, BCL6, 
Patients All
Number 16
Female 3 19%
Male 13 81%
Age, years (range) 66 (52–80)
Time from diagnosis to inclusion, years 
median (range) 6.8 (0–22.5)
Laboratory workup at baseline (median, range)
Hemoglobin (g/dL) 10.3 (7.9–13.4)
Leukocytes (x109/L) 5.9 (2.3–64.4)
Platelets (x109/L) 155.5 (56–357)
Lactate dehydrogenase (U/L) 562.5 (195–1841)
Cretinine (micromol/L) 97 (41–185)
Treatment prior to blood sample delivery*
Hydroxyurea as monotherapy 4
Hydroxyurea as supplement** 5
Alpha-interferon 5
Anagrelide 1
Darbepoetin alfa*** 3
Dynamic International Prognostic Scoring System (DIPSS)
Low-risk 1
Intermediate risk 1 9
Intermediate risk 2 3
High-risk 2
Intermediate risk 2 or high-risk**** 1
Table 1. Clinical characteristics of the MF patients. *Patients had not received any drugs prior to blood sample 
delivery. **Patients developing ischemic symptoms were given hydroxyurea to control platelet levels. ***A 
single patient had previously been treated with both darbepoetin alfa and alpha-interferon. ****The blastcount 
was not known for a single patient meaning that this patient was either in intermediate risk 2 group or scored as 
a high risk patient.
www.nature.com/scientificreports/
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TRPM2, ADORA1, ADORA2A, TFA2PA, and DIRC2 were differentially methylated in the ASXL1 mutated cases 
(Table S7).
ASXL1 mutations correlate with differential methylation in CpG rich regions in MF CD34+ 
cells. We mapped the 308 “ASXL1 methylation signature” CpG sites according to genomic regions. In samples 
with ASXL1 mutations, 36% of the differentially methylated CpG sites mapped to promoter regions, 31% to gene 
bodies, 30% to intergenic regions, and 3% to 3′UTRs (Fig. 5A). The majority of these regions were CG rich with 
36% of the affected areas categorized as CpG islands and 37% as CpG shores (Fig. 5B).
ASXL1 methylation signature probes are enriched in regions that carry H3K27me3, H3K4me1, 
and H3K27me3 plus H3K4me3 in CD34+ cells. Regions enriched with the repressive mark H3K27me3 
and the bivalent histone mark H3K27me3 plus H3K4me3 were found to have a significantly higher number of 
differentially methylated CpG sites in ASXL1 mutated cases (Fig. 5C). Both hypo- and hypermethylation of CpG 
sites were observed in regions enriched for H3K27me3 and H3K27me3 plus H3K4me3 histone marks (Table S5). 
In addition, regions enriched with H3K4me1 in CD34+ cells were also found to have a significant higher number 
of differentially methylated CpG sites in patients with ASXL1 mutations compared to non-mutated ASXL1 cases 
(Fig. 5C) of which the majority of the CpG sites (93/120) were hypomethylated (Table S5).
Discussion
As MF involves both hematopoietic progenitors and more mature cells, a broad spectrum of cells throughout the 
myeloid compartment may be affected, but the contribution of the individual cell types to MF pathogenesis has 
not previously been explored. A previous study has shown correlation of ASXL1 mutations to a higher overall 
DNA methylation level and leukemic transformation in MF, whereas TET2 mutations correlated with increased 
DNA methylation levels of a distinct set of genes11, however, that study was based on the analyses of only 12 cases 
and needs confirmation in a larger cohort.
In our study, DNA methylation profiling of sorted MF cells and normal counterparts revealed that all three 
cell populations studied were characterized by distinct differential DNA methylation patterns. Interestingly, we 
Patient 
ID
Chromosomal region 
(UCSC hg 19) Gene
Nucleotide 
change
Amino acid 
change Predicted function
1 chr20: 31,022,614 ASXL1 c.2099 InsGAG p.Y700X Premature termination
1 chr4:106,156,154 TET2 c.1118 Del T p.L392X Premature termination
1 chr9:5,073,770 JAK2 c.1849G > T p.V617F Activating mutation
2 chr1:43,815,009 MPL c.1544 G > T p.W515L Activating mutation
3 chr20:31,022,592 ASXL1 c.2077 C > T p.R693X Premature termination
3 chr20:31,022,784 ASXL1 c.2269del(25 bp) Q757fs*6 Frameshift
3 chr19: 13,054,572 CALR c.1099del(52 bp) p. L367fs*46 Frameshift causing mutant C-terminal
4 chr9:5,073,770 JAK2 c.1849G > T p.V617F Activating mutation
5 chr20:31,022,983 ASXL1 c.2468 T > A p.L823X Premature termination
5 chr4:106,158,419 TET2 c.3383 C > A p.S1128X Premature termination
5 chr9:5,073,770 JAK2 c.1849G > T p.V617F Activating mutation
6 chr19: 13,054,572 CALR c.1099del(52 bp) p. L367fs*46 Frameshift causing mutant C-terminal
7 chr20:31,023,472 ASXL1 c.2957 A > G p.N986S
7 chr9:5,073,770 JAK2 c.1849G > T p.V617F Activating mutation
8 chr9:5,073,770 JAK2 c.1849G > T p.V617F Activating mutation
9 chr9:5,073,770 JAK2 c.1849G > T p.V617F Activating mutation
10 chr20:31,023,717 ASXL1 c.3202 C > T p.R1068X Premature termination
10 chr1:43,815,009 MPL c.1544 G > T p.W515L Activating mutation
11 chr9:5,073,770 JAK2 c.1849G > T p.V617F Activating mutation
12 chr4:106,155,778 TET2 c.742 G > T p.E248X Premature termination
12 chr9:5,073,770 JAK2 c.1849G > T p.V617F Activating mutation
13* chr9:5,073,770 JAK2 c.1849G > T p.V617F Activating mutation
14 chr20:31,022,817 ASXL1 c.2302 C > T p.Q768X Premature termination
14 chr9:5,073,770 JAK2 c.1849G > T p.V617F Activating mutation
15 chr20:31,022,450 ASXL1 c.1935insG p.G646Wfs*12 Premature termination
15 chr9:5,073,770 JAK2 c.1849G > T p.V617F Activating mutation
16 chr19: 13,054,572 CALR c.1099del(52 bp) p. L367fs*46 Frameshift causing mutant C-terminal
Table 2. Mutational status of ASXL1, TET2, JAK2, CALR, and MPL in the MF patients. *Patient sample 13 was 
only screened for JAK2 mutations due to limited material.
www.nature.com/scientificreports/
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observed that the majority of differentially methylated CpG sites were only differentially methylated in particular 
cellular compartments. This is likely indicative that, within each individual cell type, different DNA methyla-
tion patterns have a specific contribution to MF pathogenesis, rather than just being associated with lineage. To 
validate the genome-wide DNA methylation data a set of 4 genes (LEP, TRIM59, ZNF577, and WT1), that were 
found hypermethylated in the CD34 + compartment, were analyzed in a validation cohort of 30 MF patients 
where DNA had been isolated from whole blood. The fact that hypermethylation was confirmed in the valida-
tion cohort underline the presence of a MF specific methylation pattern, and opens up the potential of DNA 
methylation-based biomarkers for clinical purposes. Of the four genes analyzed in our validation cohort WT1 is 
especially interesting as it is found upregulated in myelofibrosis23, which corresponds to our finding of increased 
gene body methylation. WT1 has been shown to contribute to the plasticity of DNA methylation by recruiting 
TET2 to target genes causing site-specific demethylation24. A functional role of the remaining three genes LEP, 
TRIM59, and ZNF577 in MF pathogenesis still needs to be established and will require functional studies.
The MF CD34+ population had most differentially methylated CpG sites and, according to the pathway anal-
yses, the genes with differentially methylated CpG sites were involved in ‘hematopoietic differentiation’, ‘cell-cycle’, 
‘cell death and survival’, and ‘cancer’, probably contributing to the increased proliferation and dedifferentiation 
observed in these cells. The mononuclear cells had the lowest number of differentially methylated CpG sites, 
but interestingly, differentially methylated genes were associated with ‘immunological disease’, ‘cell death and 
survival’, and ‘cancer’. These aberrations may at least to some extent be linked to the high level of inflammation 
observed in MPN25, 26. Further sorting of the mononuclear cells could potentially reveal a more profound under-
standing of the contribution from the different subtypes. Genes that were found differentially methylated in the 
granulocytes were involved in ‘inflammatory disease’, ‘cell cycle’, ‘hematological disease’, and ‘cancer’. These data 
Figure 3. RPMM clustering of the granulocytes and their healthy age-matched counterparts with overlaid 
mutational status. Fifteen samples were analyzed for mutations in ASXL1, TET2, IDH1, IDH2, DNMT3A, CALR, 
JAK2, and MPL, while sample 13 was only analyzed for JAK2 mutations. The upper purple panel: Dynamic 
International Prognostic Scoring System (DIPSS). *The blast count was not available for MF patient F14. The 
middle black and red panel: Mutational status (black represents a mutation). Mutations were found for ASXL1, 
TET2, JAK2, CALR, and MPL. Lower panel: Hierarchical clustering of methylation levels in granulocytes 
from MF patients and healthy age-matched controls. β values range from 0 (blue; unmethylated) to 1 (red; 
methylated). Columns represent samples and rows represent differentially methylated CpG sites. Euclidean 
distance and complete linkage were used to study the cluster pattern of differential methylated probes. None of 
the mutations analyzed were associated with a DNA methylation-based subgrouping.
www.nature.com/scientificreports/
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imply that specific characteristics of the malignant clones in the individual cellular compartments may contribute 
to different aspects of the MF phenotype.
Since DNA methylation has been associated with mutations in epigenetic regulators we next analyzed the 
mutational status of epigenetic regulators in our MF cohort. Sequencing analyses showed that ASXL1 was 
mutated in 7/15 (47%) patients, where a premature stop codon predicted to result in truncation in six cases, 
indicating that normal ASXL1 function may be lost. TET2 mutations were observed in 3/15 (20%). Thus, the 
frequency of mutations observed in our cohort is consistent with that of others, who report ASXL1 mutations in 
20–55%14, 27, 28, and TET2 mutations in 14–20%29, 30. Mutations of IDH1, IDH2 and DNMT3A in MF are infre-
quent ranging from 0–7%14, 29–32.
With 7/15 patients having ASXL1 mutations, we aimed to investigate the ASXL1 mutation associated DNA 
methylation signature in MF. In contrast to a previous study of 12 patients11, we did not find ASXL1 mutations to 
be associated with an overall higher level of DNA methylation, or a distinct DNA methylation profile in either the 
granulocytes or the CD34+ cells using an unsupervised approach. However, when using supervised clustering 
analysis in the CD34+ cells a subset of differentially methylated CpG sites, frequently located in tumor suppres-
sors and oncogenes, were found in ASXL1 mutated cases.
The majority of differentially methylated CpG sites associated with the “ASXL1 methylation signature” in 
CD34+ cells were enriched in regions with the repressive histone mark H3K27me3, whereas a minor proportion 
of the differentially methylated CpG sites were enriched in regions with the bivalent histone mark H3K27me3 
plus H3K4me3. This is remarkable because ASXL1 has been suggested to regulate histone H3K27 methylation 
through interactions with the Polycomb-repressive complex 2 (PRC2). However, the association between ASXL1 
mutation, H3K27me3, and differential DNA methylation is not straight forward and warrants further study. 
Differentially methylated CpG sites in ASXL1 mutated cases were also found in regions with the active histone 
mark H3K4me1, found at enhancer regions, which is likely to influence transcription of nearby genes. Most of the 
CpG sites overlapping with H3K4me1 were hypomethylated, and may thus possibly be associated with enhancer 
activation. Several genes previously recognized as tumor suppressors and oncogenes in other cancers including 
e.g. RASSF1, miR-663, ARID5B, FIP1L1, BCL6, TRPM2, ADORA1, ADORA2A, TFA2PA, and DIRC2 were among 
the “ASXL1 methylation signature genes”. Our data indicate that truncated ASXL1 is associated with methylation 
Figure 4. Hierarchical clustering of 308 differentially methylated CpG sites in MF CD34+ cells associated with 
ASXL1 mutations using Pearson correlation and Average distance. Green indicates hypomethylated CpG sites 
and red indicates hypermethylated CpG sites. Columns represent the 15 MF patients analyzed. Rows represent 
differentially methylated CpG sites in MF CD34+ cells in ASXL1 mutated (n = 7) and ASXL1 non-mutated 
(_NM) (n = 8) cases.
www.nature.com/scientificreports/
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changes of a distinct set of cancer related genes that may be involved in disease progression, although no direct 
link between ASXL1 and DNA methylation has yet been established. Extending these analyses to TET2 mutated 
cases had been interesting but with only three MF patients carrying a TET2 mutation, of which two also had an 
ASXL1 mutation, we decided to focus on ASXL1 only. In addition, it would have been interesting to extent these 
analyses to JAK2 as JAK2 has been shown to influence the chromatin directly by phosphorylation of histone 
H3 tyrosine 4133. Indirectly, through the phosphorylation of PRMT5, mutated JAK2V617F has been shown to 
result in reduced methylation at histone H2A or H4 at R334. A direct link between JAK2 and DNA methylation 
is, however, missing and previous studies have not shown any association between JAK2 mutations and DNA 
methylation in myelofibrosis11, 12.
Taken together we found that aberrant and variable methylation patterns are present in the different myeloid 
cell compartments of MF patients. The differentially methylated CpG sites are annotated to several tumor sup-
pressor genes and oncogenes, but also to genes involved mainly in inflammation and immunological diseases. 
Thus, the MF phenotype is likely a result of the aberrant function of distinct cell types throughout the myeloid 
lineages. In addition, we found that ASXL1 mutations are associated with DNA methylation changes in regulatory 
regions of cancer associated genes, not previously associated with MF. In future studies it shall be interesting to 
explore if there is a direct link between ASXL1 mediated gene regulation and aberrant methylation of these genes 
in malignant myelopoiesis.
Methods
Patient material and controls. This study is based on a primary cohort of 16 MF patients and three 
healthy age-matched controls and a validation cohort of 30 MF patients and 11 healthy controls. Clinical char-
acteristics of the primary MF cohort including the Dynamic International Prognostic Scoring System (DIPSS) 
are shown in Table 1. For the primary cohort peripheral blood was separated into granulocytes and mononuclear 
cells using a Ficoll gradient. As a consequence of fibrotic bone marrow and extramedullary hematopoiesis, MF 
CD34+ cells could be isolated from the fraction of mononuclear cells using a CD34 + positive selection kit on 
a RoboSepTM platform (Stemcell Technologies, Grenoble, France). CD34+ cells from bone marrow, peripheral 
blood granulocytes, and mononuclear cells from three healthy age-matched individuals were used as controls. 
DNA was extracted using the AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany).
DNA from whole blood was extracted from the validation cohort using the Autopure LS (Qiagen) instrument 
and the Gentra Puregene Blood Kit (Qiagen), respectively.
Figure 5. The relative distribution of the differentially methylated CpG sites associated with ASXL1 mutations 
in CD34 + MF cells. (A) Functional genomic distribution in gene body, 3’UTR, intergenic, and promoter; and 
(B) mapping according to the CpG density to islands, shelf, shore, and others/open sea. The majority of CpG 
sites were mapped to CpG shores (37%) and CpG islands (36%). (C) ASXL1 associated differentially methylated 
CpG sites were enriched in regions enriched for the histone marks H3K4me1 (P = 0.004), H3K27me3 
(P = 1.10E-05), and the bivalent mark H3K27me3 plus H3K4me3 (P = 2.00E-03) in healthy CD34+ cells.
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The study was approved by the regional ethical committee (De Videnskabsetiske Komitéer Region 
Hovedstaden, Journal: H-C-2008–079) and all experiments were performed in accordance with the approved 
guidelines and regulations. All patients included had given a written informed consent.
Genome-wide DNA methylation profiling. Genome-wide DNA methylation profiling was performed 
using the 450 K Infinium array (Illumina Inc, San Diego, USA) platform as desribed previously35. This platform 
interrogates the methylation status of more than 480,000 CpGs in the human genome corresponding to 99% of 
NCBI RefSeq genes, which include CpGs in the promoters, enhancers, and gene bodies among others. In addition, 
the array covers CpG islands, shores and shelves of CpG islands. After hybridization and scanning of BeadChips, 
IDAT files were extracted to calculate the DNA methylation score (β values) ranging from 0 (non-methylated) to 
1 (fully methylated) as described previously35.
Data filtering and normalization of DNA methylation data: Measurements in which the fluorescence inten-
sity was not statistically significant above background signal were removed from the data set. Through an initial 
filtering process, probes corresponding to X and Y chromosomes and those containing a single nucleotide pol-
ymorphism (SNP) within five base pairs of targeted CpG sites were excluded. Probes with a repetitive element 
in the probe sequence within five bases of the targeted CpG site were also excluded. In total 361974 probes were 
used for further analysis.
Differential methylation between the MF samples and healthy control samples of individual CpG sites for each 
cell type was calculated. The probes with a FDR p < 0.05 in t-test and Δβ >  ± 0.2 were considered to be differen-
tially methylated as previously described35, with the exception of the granulocytes for which a mean Δβ >  ± 0.3 
was used with an adjusted p value < 0.01. For visualization, RPMM (recursively partitioned mixture model) and 
hierarchical clustering approaches were used. Hierarchial clustering using Euclidean distance and average linkage 
was used to classify samples into various groups as described previously36. All statistical analyses and clustering 
were performed using a R-statistical packages (https://www.r-project.org/) as described previously35, 37.
Pathway analysis. Functional interpretation of genes with one or more significantly differentially meth-
ylated CpG sites annotated was analyzed in the context of gene ontology and molecular networks by using 
Ingenuity pathway software (IPA; www.ingenuity.com) as described previously35.
Enrichment analysis. To investigate whether differentially methylated CpG sites were enriched in 
regions with distinct histone modifications, including H3K4me1, H3K4Me3, H3K4me3 plus H3K27me3, and 
H3K27me3, ChIP-seq data from human CD34+ cells was downloaded from NIH roadmap Epigenomics map-
ping consortium (http://www.roadmapepigenomics.org/) and GSE36994, and the coordinates of ChIP-seq peaks 
were mapped to the 450 K probe locations. A hypergeometric test was used to evaluate possible enrichment of 
differentially methylated CpG sites in regions with distinct histone modifications.
Validation of differentially methylated sites using pyrosequencing. Four genes (LEP, TRIM59, 
WT1, and ZNF577) with at least two differentially methylated CpG sites in close proximity to the transcrip-
tion start site (Table S1) were further analyzed in whole blood from a validation cohort of 30 MF patients and 
11 healthy controls. Methylation independent (MIP) assays38 were designed using the PyroMark Assay Design 
2.0 (Qiagen). The PCR amplicons were pyrosequenced on the PyroMark Q24 (Qiagen) instrument using the 
PyroMark Gold Q24 reagents (Qiagen) according to manufacturers’ instructions. For each of the four genes the 
DNA methylation level is calculated as the median DNA methylation level of the CpG sites included in the assay 
(Table S1). Primer sequences and PCR conditions are given in Table S1.
Mutation analysis. Mutation analyses were performed on DNA extracted from MF granulocytes. The 
primer sequences and assay conditions for the mutation analyses of the genes of interest have previously been 
published; TET2, IDH1, IDH2, DNMT3A35, JAK239, CALR7, and MPL40. ASXL1 exon 12 was analyzed for muta-
tions as previously described15 with modifications for two assays (Table S1). M13 tagged primers were used for 
CALR, ASXL, and MPL.
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